SCHEMBL266306

SCHEMBL266306

O=C(Nc1ccc(Br)cc1C(=O)NN=Cc1ccc(Cl)c(C(F)(F)F)c1)c1ccc(CSc2ccncc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
NPC1 O15118 3/20 0.40
PKM P14618 3/20 0.40
RAB9A P51151 2/20 0.40
ALDH1A1 P00352 1/20 0.39
HTT P42858 3/20 0.39
KCNK2 O95069 1/20 0.39
KCNK10 P57789 1/20 0.39
RECQL P46063 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
SLC34A2 O95436 2/20 0.37
SLC34A1 Q06495 1/20 0.37
SLC34A3 Q8N130 1/20 0.37
SLC20A1 Q8WUM9 1/20 0.37
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273401 1.00 MAPT (0.42) MAPTGAALMNAPOLBNPC1
SCHEMBL267708 0.92 SLC34A2 (0.46) MAPTLMNAPOLBNPC1PKM
SCHEMBL273541 0.92 SLC34A2 (0.46) MAPTLMNAPOLBNPC1PKM
SCHEMBL267373 0.89 NPC1 (0.48) MAPTGAALMNAPOLBNPC1
SCHEMBL273927 0.89 NPC1 (0.48) MAPTGAALMNAPOLBNPC1
SCHEMBL267372 0.89 NPC1 (0.48) MAPTGAALMNAPOLBNPC1
SCHEMBL266677 0.87 POLB (0.41) MAPTGAALMNAPOLBNPC1
SCHEMBL274042 0.87 POLB (0.41) MAPTGAALMNAPOLBNPC1
SCHEMBL266678 0.87 POLB (0.41) MAPTGAALMNAPOLBNPC1
SCHEMBL273396 0.86 NPC1 (0.51) MAPTGAALMNAPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885GAA 1336/4885LMNA 2001/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885GAA 1640/4885LMNA 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.